Industry Trends

The Amcor-Bemis Acquisition: A Procurement Manager's FAQ on What Changed (and What Didn't)

The Amcor-Bemis Acquisition: A Procurement Manager's FAQ on What Changed (and What Didn't)

Look, when a big industry move like the Amcor-Bemis acquisition happens, the press releases are full of "synergies" and "enhanced capabilities." But if you're the one managing a packaging budget, you have real questions. Will my prices go up? Is my supply chain more stable or less? What's the actual impact on my day-to-day?

I'm a procurement manager at a 150-person medical device company. I've managed our flexible and sterile packaging budget (about $220,000 annually) for six years, negotiated with 50+ vendors, and tracked every invoice in our system. When the Amcor-Bemis news broke, I wasn't thinking about market share. I was thinking about my POs, my lead times, and my total cost of ownership (TCO).

Here are the answers I needed—and found—based on actual experience and post-acquisition orders.

1. Did the Amcor-Bemis deal immediately change my pricing?

Short answer: Not directly, but the landscape shifted.

To be fair, I didn't get a letter saying "Due to the merger, your film costs are now 10% higher." It's more subtle. In Q3 2024, when I was comparing quotes for a new line of pouches, I noticed something. The bids from what used to be "just Bemis" suppliers were now structured more like Amcor bids. Slightly different fee breakdowns, different minimum order quantities (MOQs).

The base price for a standard barrier film was competitive. But the setup and plate fees? They were consolidated differently. I almost missed it. When I calculated the TCO for the first 12 months, the "cheaper" base price option came out 8% higher due to those restructured fees. That's a classic post-integration move—consolidating backend costs. You have to look at the whole picture, not just the line item.

2. Is my supply chain more reliable now?

Here's the thing: It should be, but verify.

On paper, being part of Amcor's global network should mean better raw material sourcing and more production redundancy. And for some standard items, lead times did stabilize. In early 2024, we had a critical order for sterile barrier packaging. The old Bemis plant had a backlog, but the rep was able to route it through an Amcor facility with spare capacity. We got it in 10 days instead of the quoted 28. That was a win.

But then again, I've heard from peers that for highly customized, legacy Bemis-specific items (certain medical device tray designs), there were transition hiccups. Drawings got lost between systems. The moral? For standard products, reliability seems up. For custom, legacy stuff, ask more questions upfront. Get confirmations in writing.

3. What about innovation? Are we getting Amcor's tech?

I'm not a material scientist, so I can't speak to the molecular-level innovations. What I can tell you from a procurement perspective is that the access to innovation changed.

Before, if we needed a high-barrier film for a new drug application, Bemis had their solutions. Now, the sales engineers can also pull from Amcor's portfolio. Last quarter, we were evaluating films for a product requiring an extreme moisture barrier. The combined team presented three options: one legacy Bemis, one legacy Amcor, and one new "hybrid" formulation they're developing. More choice is good.

The catch? It takes more time to evaluate. You need to be clear on your specs, or you'll drown in options.

4. Should I be worried about becoming a "small fish" in a big pond?

This was my biggest concern. A giant global entity doesn't care about my $220k annual spend, right?

My experience so far: it's a mixed bag. Our dedicated account rep stayed the same—a huge plus. She knows our history. But the support structure behind her is definitely more corporate. Billing is centralized. Credit approvals take longer. Need a one-time deviation from spec? The approval chain has more links.

It took me 3 years and about 150 orders with the old Bemis to build a relationship where I could get a favor. That dynamic is different now. It's more process-driven. Not necessarily worse, just... different. More formal.

5. What's the one thing most people miss when evaluating suppliers post-acquisition?

Continuity of people.

Everyone looks at products and prices. The real risk is in turnover. After the acquisition, there was reshuffling. Our fantastic quality liaison on the West Coast took a package and left. The new person is capable, but doesn't know our weird, legacy approval quirks. We had a shipment held up for a week over a documentation formatting issue that the old contact would have smoothed over in an email.

When a big merger happens, always ask: "Who is my day-to-day contact, and are they staying?" Get it in the notes. The value of a person who knows your account is a hidden cost if you lose it.

6. So, bottom line: has it been good or bad for buyers?

It's not that simple. Seriously.

For standardized, high-volume packaging (like certain flexible films), it's probably a net positive. More stability, potentially better pricing on bulk, access to a wider tech base.

For specialized, low-volume, or highly customized packaging (like complex medical device kits), it's riskier. You might face more rigid processes, less flexibility, and the hidden costs of re-qualifying materials if production shifts plants.

My advice? Don't assume anything. Audit your last 12 months of spending with them. Re-calculate the TCO on your key items as if you were a new customer. And always, always have a qualified backup supplier ready. That's the best cost control move you can make, merger or no merger.